Analysis of Ivacaftor drug approval for cystic fibrosis patients with gating mutations.
Cystic fibrosis is an inherited monogenetic disorder that leads to chronic respiratory and lung infections. These infections result in decreased quality of life in patients. Quality of life (QOL) can be attributed to many disease characteristics such as hospitalization, organ transplant, depression,...
Saved in:
| Main Author: | Nemirajaiah, S. |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Royal St. George's College
2021-08-01
|
| Series: | The Young Researcher |
| Subjects: | |
| Online Access: | http://www.theyoungresearcher.com/papers/nemirajaiah.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
by: Burkhard Tümmler, et al.
Published: (2025-05-01) -
Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction
by: Alice Castaldo, et al.
Published: (2025-07-01) -
A severe early presentation of cystic fibrosis in an infant with a homozygous c.1375_1383del CFTR variant- a case report
by: Abdullah Yousef, et al.
Published: (2025-08-01) -
Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor
by: Espérie Burnet, et al.
Published: (2025-09-01) -
Novel Co‐Occurrence of Trisomy 21 and Heterozygous CFTR Mutation
by: Majd Oweidat, et al.
Published: (2025-04-01)